ANDA 89146, held by Par Pharm. Hydroxyzine Pamoate.
As of Nov 15, 2026, ANDA 89146 (Hydroxyzine Pamoate), held by Par Pharm, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxyzine PamoateEQ 50MG HYDROCHLORIDE ยท capsule;oral | Hydroxyzine Pamoate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
